FindTrial
Sign In

The role of hemoperfusion in COVID-19

Comparison of therapeutic effects of hemoperfusion in intubated and non-intubated patients with respiratory failure caused by the COVID-19

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200608047686N2
Enrollment
40
Registered
2020-11-19
Start date
2020-10-17
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention group: 40 eligible patients with severe COVID-19 in a 1:1 ratio: (20 intubated and 20 non-intubated)hemoperfusion + Standard of care treatment.

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Hospitalized patients with respiratory failure caused by the COVID-19

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
O2 Saturation. Timepoint: Before and after the sessions of hemoperfusion. Method of measurement: Pulse Oximetry.;CRP. Timepoint: Before and after the sessions of hemoperfusion. Method of measurement: Blood level.;Ferritin. Timepoint: Before and after the sessions of hemoperfusion. Method of measurement: Blood level.;Vasopressor need. Timepoint: Before and after the sessions of hemoperfusion. Method of measurement: Observation.—

Secondary

MeasureTime frame
Lenght of hospitat stay. Timepoint: Daily up to discharge. Method of measurement: Days of hospitalization.;Mortality. Timepoint: Daily up to 28 days. Method of measurement: Observation.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMuhanna Kazempour

Shahid Beheshti University of Medical Sciences

muhannakazempour@gmail.com+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026